Realizing individualized cancer treatment through patient genome sequencing

Recent Publications

Papadopoulos, K. P., Borazanci, E., Shaw, A. T., katayama, R., Shimizu, Y., Zhu, V. W., sun, T. Y., Wakelee, H. A., Madison, R., Schrock, A. B., Senaldi, G., Nakao, N., Hanzawa, H., Tachibana, M., Isoyama, T., Nakamaru, K., Deng, C., Li, M., Fran, F., Zhao, O., Gao, Y., Seto, T., Janne, P. A. and Ou, S. H. I.
US phase 1 first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors.
Clin. Cancer Res., in press (2020)
Arai, S., Takeuchi, S., Fukuda, K., Taniguchi, H., Nishiyama, A., Tanimoto, A., Satouchi, M., Yamashita, K., Ohtsubo, K., Nanjo, S., Kumagai, T., Katayama, R., Nishio, M., Zheng, M. M., Wu, Y. L., Nishihara, H., Yamamoto, T., Nakada, M. and Yano, S.
Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer.
J. Thorac. Oncol., 15, 752-765 (2020)
Ono, F., Chiba, S., Isaka, Y., Matsumoto, S., Ma, B., Katayama, R., Araki, M. and Okuno, Y.
Improvement in predicting drug sensitivity changes associated with protein mutations using a molecular dynamics based alchemical mutation method.
Sci. Rep., 10, 2161 (2020)
Yanagitani, N., Uchibori, K., Koike, S., Tsukahara, M., Kitazono, S., Yoshizawa, T., Horiike, A., Ohyanagi, F., Tambo, Y., Nishikawa, S., Fujita, N., Katayama, R. and Nishio, M.
Drug resistance mechanisms in Japanese ALK positive NSCLC and the clinical responses based on the resistant mechanisms.
Cancer Sci., 111, 932-939 (2020)
Fujimura, A., Hayashi, Y., Kato, K., Kogure, Y., Kameyama, M., Shimamoto, H., Daitoku, H., Fukamizu, A., Hirota, T. and Kimura, K.
Identification of a novel nucleolar protein complex required for mitotic chromosome segregation through centromeric accumulation of Aurora B.
Nucleic Acids Res., in press (2020)

more